CN Patent

CN113365997B — 作为c-Met抑制剂的含嘧啶基团的三并环类化合物

Assigned to Jiangsu Aosaikang Pharmaceutical Co Ltd · Expires 2022-06-07 · 4y expired

What this patent protects

公开了一类含嘧啶基团的三并环类化合物，及其在制备治疗癌症的药物中的应用。具体公开了式(I)所示化合物、其药学上可接受的盐或其异构体。

USPTO Abstract

公开了一类含嘧啶基团的三并环类化合物，及其在制备治疗癌症的药物中的应用。具体公开了式(I)所示化合物、其药学上可接受的盐或其异构体。

Drugs covered by this patent

tepotinib-hydrochloride (TEPOTINIB HYDROCHLORIDE)

Patent Metadata

Patent number: CN113365997B
Jurisdiction: CN
Classification: —
Expires: 2022-06-07
Drug substance claim: No
Drug product claim: No
Assignee: Jiangsu Aosaikang Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.